Compare Newmont Corporation (NEM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Newmont Corporation trades at $111.91 (market cap $121.80B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Newmont Corporation is far larger — about 16.2× Spyre Therapeutics Inc. Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NEM | SYRE | |
|---|---|---|
Market Cap | $121.80B | $7.52B |
Volume | 4,383,120 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $108.92 |
52-Week Low | $78.63 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $118.39B | $6.52B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $111.56, down 4.77% over the past 24 hours, with strong fundamental performance including record free cash flow of $5.3 billion in H1 2026 and three consecutive quarterly earnings beats. The stock shows a bullish technical signal with moving averages supporting upward momentum, while maintaining attractive valuation metrics including a P/E of 14.58 and EV/EBITDA of 7.38. Recent news highlights the company's focus on per-share growth and operational improvements amid constructive gold market conditions.
Newmont presents a compelling investment case with robust profitability (33.36% net margin), strong analyst consensus (76% buy ratings), and 22% upside to the $136.83 price target. Key risks include gold price volatility and execution of growth initiatives, but the company's record cash flow generation and improving balance sheet provide solid foundation for continued shareholder value creation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
